MF59 is a safe and potent vaccine adjuvant for flu Vaccines in humans: What did we learn during its development?

被引：68

作者：

O'Hagan, D. T. ^{[1
]}

Wack, A. ^{[1
]}

Podda, A. ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost Inc, Siena, Italy

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 82卷 / 06期

关键词：

D O I：

10.1038/sj.clpt.6100402

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The MF59 adjuvant has been included in a licensed influenza vaccine for a decade. Hence, we have a significant amount of clinical data to establish its potency and safety. We can now reassess our early preclinical studies and determine whether or not they were useful to predict human responses. The main lesson learned is that mouse models can be valuable, but one must ask the right questions and the models must be used appropriately.

引用

收藏

页码：740 / 744

页数：5

相关论文

共 37 条

[1]

[Anonymous], ADV DRUG DELIV REV

[2] Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations [J].

Atmar, Robert L. ;

Keitel, Wendy A. ;

Patel, Shital M. ;

Katz, Jacqueline M. ;

She, Dewei ;

El Sahly, Hana ;

Pompey, Justine ;

Cate, Thomas R. ;

Couch, Robert B. .

CLINICAL INFECTIOUS DISEASES, 2006, 43 (09) :1135-1142

[3] Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases [J].

Baldo, V. ;

Baldovin, T. ;

Floreani, A. ;

Fragapane, E. ;

Trivello, R. .

JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (05) :542-547

[4] MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications [J].

Baldo, V. ;

Baldovin, T. ;

Floreani, A. ;

Carraro, A. M. ;

Trivello, R. .

VACCINE, 2007, 25 (20) :3955-3961

[5] A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis [J].

Banzhoff, A ;

Nacci, P ;

Podda, A .

GERONTOLOGY, 2003, 49 (03) :177-184

[6] Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial [J].

Bresson, Jean-Louis ;

Perronne, Christian ;

Launay, Odile ;

Gerdil, Catherine ;

Saville, Melanie ;

Wood, John ;

Hoeschler, Katja ;

Zambon, Maria C. .

LANCET, 2006, 367 (9523) :1657-1664

[7] THE INFLUENCE OF ADJUVANT ON THE THERAPEUTIC EFFICACY OF A RECOMBINANT GENITAL HERPES VACCINE [J].

BURKE, RL ;

GOLDBECK, C ;

NG, P ;

STANBERRY, L ;

OTT, G ;

VANNEST, G .

JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (05) :1110-1119

[8] The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice [J].

Cataldo, DM ;

VanNest, G .

VACCINE, 1997, 15 (16) :1710-1715

[9]

Chernoff D, 1995, VACCINE DESIGN SUBUN, P277

[10] An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine [J].

Del Giudice, G ;

Hilbert, AK ;

Bugarini, R ;

Minutello, A ;

Popova, O ;

Toneatto, D ;

Schoendorf, I ;

Borkowski, A ;

Rappuoli, R ;

Podda, A .

VACCINE, 2006, 24 (16) :3063-3065

← 1 2 3 4 →